Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 2/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 4/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 6/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23952766 | 0.89 | FFAR1 (0.42) | PRKCQPRKCDPIM1PIM2CNR2 | |
| SCHEMBL16845954 | 0.89 | FFAR1 (0.42) | PRKCQPRKCDPIM1PIM2CNR2 | |
| SCHEMBL29423951 | 0.88 | FFAR1 (0.39) | PRKCQPRKCDPIM1PIM2CNR2 | |
| SCHEMBL23952822 | 0.85 | FFAR1 (0.43) | PIM1PIM2CNR2ABL1FFAR1 | |
| SCHEMBL18959437 | 0.77 | FFAR1 (0.34) | PIM1FFAR1 | |
| SCHEMBL18959445 | 0.77 | FFAR1 (0.39) | FFAR1 | |
| SCHEMBL23952770 | 0.76 | FFAR1 (0.41) | CNR2FFAR1 | |
| SCHEMBL18959417 | 0.74 | CD274 (0.38) | FFAR1 | |
| SCHEMBL18959443 | 0.72 | FFAR1 (0.35) | PTGS1PTGS2FFAR1 | |
| SCHEMBL18959460 | 0.71 | FFAR1 (0.35) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | GPR119, GPR65, GPR55 | PRKCQ 1531/4885PRKCD 1350/4885PIM1 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.